Augmentin Es-600

Urinary Tract Infections, Sinusitis, Gonorrhea + 11 more
Treatment
2 FDA approvals
20 Active Studies for Augmentin Es-600

What is Augmentin Es-600

AmoxicillinThe Generic name of this drug
Treatment SummaryAmoxicillin, also known as BRL-2333, is an antibiotic derived from penicillin G. It is similar to penicillin and ampicillin but can reach higher levels in the bloodstream. Amoxicillin was approved by the FDA in 1974.
Amoxicillinis the brand name
image of different drug pills on a surface
Augmentin Es-600 Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Amoxicillin
Amoxicillin
1978
1067

Approved as Treatment by the FDA

Amoxicillin, also called Amoxicillin, is approved by the FDA for 2 uses including Duodenal Ulcer and Duodenal ulcer caused by helicobacter pylori .
Duodenal Ulcer
Used to treat Duodenal ulcer caused by helicobacter pylori in combination with Clarithromycin
Duodenal ulcer caused by helicobacter pylori
Used to treat Duodenal ulcer caused by helicobacter pylori in combination with Clarithromycin

Effectiveness

How Augmentin Es-600 Affects PatientsAmoxicillin inhibits certain proteins related to the synthesis of the bacterial cell wall. This allows the body to destroy the bacteria. It is usually taken twice daily and has a wide range of safety, so mild overdoses are not too dangerous. Patients should be aware of the risk of anaphylaxis, infections caused by the bacteria _Clostridium difficile_, and the potential for bacteria to become resistant to the drug.
How Augmentin Es-600 works in the bodyAmoxicillin works by blocking bacteria's ability to build and repair their cell wall. It does this by stopping penicillin-binding proteins, which are responsible for adding cross-links between D-alanine and D-aspartic acid molecules in the cell wall. Without these proteins, bacteria cannot create a strong enough cell wall to survive, so they die off.

When to interrupt dosage

The prescribed dosage of Augmentin Es-600 is contingent upon the specified condition, such as Lower Respiratory Tract Infection (LRTI), Duodenal Ulcer and Stomach Ulcer. The measure may vary as per the technique of administration (e.g. For suspension - Oral or Oral) mentioned in the following table.
Condition
Dosage
Administration
ear, nose, and throat infections
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Tablet, chewable, Tablet, chewable - Oral, Kit, Suspension - Oral, Capsule, Capsule - Oral, Suspension, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension - Oral, Tablet, for suspension, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release, Capsule, delayed release - Oral
Gonorrhea
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Tablet, chewable, Tablet, chewable - Oral, Kit, Suspension - Oral, Capsule, Capsule - Oral, Suspension, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension - Oral, Tablet, for suspension, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release, Capsule, delayed release - Oral
Sinusitis
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Tablet, chewable, Tablet, chewable - Oral, Kit, Suspension - Oral, Capsule, Capsule - Oral, Suspension, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension - Oral, Tablet, for suspension, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release, Capsule, delayed release - Oral
Bronchitis
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Tablet, chewable, Tablet, chewable - Oral, Kit, Suspension - Oral, Capsule, Capsule - Oral, Suspension, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension - Oral, Tablet, for suspension, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release, Capsule, delayed release - Oral
Otitis
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Tablet, chewable, Tablet, chewable - Oral, Kit, Suspension - Oral, Capsule, Capsule - Oral, Suspension, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension - Oral, Tablet, for suspension, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release, Capsule, delayed release - Oral
ABDIC protocol
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Tablet, chewable, Tablet, chewable - Oral, Kit, Suspension - Oral, Capsule, Capsule - Oral, Suspension, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension - Oral, Tablet, for suspension, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release, Capsule, delayed release - Oral
Duodenal Ulcer
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Tablet, chewable, Tablet, chewable - Oral, Kit, Suspension - Oral, Capsule, Capsule - Oral, Suspension, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension - Oral, Tablet, for suspension, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release, Capsule, delayed release - Oral
Bacterial Infections
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Tablet, chewable, Tablet, chewable - Oral, Kit, Suspension - Oral, Capsule, Capsule - Oral, Suspension, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension - Oral, Tablet, for suspension, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release, Capsule, delayed release - Oral
Urinary Tract Infection (UTI)
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Tablet, chewable, Tablet, chewable - Oral, Kit, Suspension - Oral, Capsule, Capsule - Oral, Suspension, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension - Oral, Tablet, for suspension, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release, Capsule, delayed release - Oral
Peptic Ulcer With H. Pylori Infection
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Tablet, chewable, Tablet, chewable - Oral, Kit, Suspension - Oral, Capsule, Capsule - Oral, Suspension, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension - Oral, Tablet, for suspension, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release, Capsule, delayed release - Oral
Community Acquired Pneumonia (CAP)
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Tablet, chewable, Tablet, chewable - Oral, Kit, Suspension - Oral, Capsule, Capsule - Oral, Suspension, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension - Oral, Tablet, for suspension, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release, Capsule, delayed release - Oral
Urinary Tract Infections
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Tablet, chewable, Tablet, chewable - Oral, Kit, Suspension - Oral, Capsule, Capsule - Oral, Suspension, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension - Oral, Tablet, for suspension, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release, Capsule, delayed release - Oral
Urinary Tract Infections
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Tablet, chewable, Tablet, chewable - Oral, Kit, Suspension - Oral, Capsule, Capsule - Oral, Suspension, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension - Oral, Tablet, for suspension, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release, Capsule, delayed release - Oral
Helicobacter Pylori Infection
, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Tablet, chewable, Tablet, chewable - Oral, Kit, Suspension - Oral, Capsule, Capsule - Oral, Suspension, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension - Oral, Tablet, for suspension, Tablet, extended release, Tablet, extended release - Oral, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release, Capsule, delayed release - Oral

Warnings

Augmentin Es-600 Contraindications
Condition
Risk Level
Notes
Liver Dysfunction
Do Not Combine
Pulse Frequency
Do Not Combine
Jaundice, Obstructive
Do Not Combine
Jaundice, Obstructive
Do Not Combine
Liver Dysfunction
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Amoxicillin may interact with Pulse Frequency
There are 20 known major drug interactions with Augmentin Es-600.
Common Augmentin Es-600 Drug Interactions
Drug Name
Risk Level
Description
Vibrio cholerae CVD 103-HgR strain live antigen
Major
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Amoxicillin.
Aclidinium
Minor
Amoxicillin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine
Minor
Amoxicillin may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Amoxicillin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Allylestrenol
Minor
Amoxicillin may decrease the excretion rate of Allylestrenol which could result in a higher serum level.
Augmentin Es-600 Toxicity & Overdose RiskPatients who have overdosed on cephalexin may have bloody urine, a lack of urine production, abdominal pain, kidney failure, vomiting, diarrhea, rash, excessive energy, or drowsiness. Treatment for overdose may involve inducing vomiting or dialysis.
image of a doctor in a lab doing drug, clinical research

Augmentin Es-600 Novel Uses: Which Conditions Have a Clinical Trial Featuring Augmentin Es-600?

60 active clinical trials are undergoing to assess Augmentin Es-600's aptitude to combat Urinary Tract Infection, ENT Infections, and Bacterial Infections.
Condition
Clinical Trials
Trial Phases
Bacterial Infections
0 Actively Recruiting
Urinary Tract Infections
0 Actively Recruiting
Duodenal Ulcer
0 Actively Recruiting
Bronchitis
2 Actively Recruiting
Not Applicable
ABDIC protocol
0 Actively Recruiting
ear, nose, and throat infections
0 Actively Recruiting
Community Acquired Pneumonia (CAP)
5 Actively Recruiting
Not Applicable, Phase 1, Phase 3
Sinusitis
2 Actively Recruiting
Not Applicable
Helicobacter Pylori Infection
2 Actively Recruiting
Not Applicable, Phase 4
Peptic Ulcer With H. Pylori Infection
0 Actively Recruiting
Urinary Tract Infections
7 Actively Recruiting
Not Applicable, Phase 4
Gonorrhea
0 Actively Recruiting
Urinary Tract Infection (UTI)
6 Actively Recruiting
Phase 1, Phase 3, Phase 4, Phase 2
Otitis
3 Actively Recruiting
Not Applicable

Augmentin Es-600 Reviews: What are patients saying about Augmentin Es-600?

4.3Patient Review
6/13/2017
Augmentin Es-600 for Skin Infection due to Staphylococcus Aureus Bacteria
Yes, the side effects can be unpleasant. But it's better than the alternative of dying.
4.3Patient Review
1/1/2008
Augmentin Es-600 for Skin Infection
I started to experience itching after only six hours.
2Patient Review
7/12/2012
Augmentin Es-600 for Middle Ear Infection
My 23 month old was vomiting by day three of taking this medication for an ear infection. I stopped giving it to him and called his doctor.
1.7Patient Review
5/31/2010
Augmentin Es-600 for Middle Ear Infection
I would not recommend this medication to anyone, especially small children. It is incredibly hard to get your child to take it because of the taste, and it caused my son a lot of pain with severe diarrhea.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about augmentin es-600

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the difference between Augmentin and Augmentin ES?

"AUGMENTIN ES-600 contains more clavulanic acid than the other AUGMENTIN suspensions."

Answered by AI

Is Augmentin a strong antibiotic?

"Does Augmentin work better than amoxicillin? Augmentin can fight against a broader range of bacteria than amoxicillin alone. Therefore, Augmentin may be considered a stronger antibiotic than amoxicillin. The potency of the antibiotic depends on the infection and the type of bacteria causing the infection."

Answered by AI

What is Augmentin ES 600 used for?

"AUGMENTIN ES-600 is an antibiotic that contains two active ingredients. One is amoxicillin, a penicillin, and the other is clavulanic acid. AUGMENTIN ES-600 is used to treat children with infections caused by bacteria."

Answered by AI

How do you mix Augmentin ES 600?

"In a separate container, measure out the rest of the water. Add it to the mixture, screw the cap back on, and shake it vigorously. Each teaspoon (5 ml) of the mixture will contain 600 mg of amoxicillin as the trihydrate and 42.9 mg of clavulanic acid as the potassium salt. Make sure to shake the oral suspension well before each use."

Answered by AI

Clinical Trials for Augmentin Es-600

Image of UPMC Magee-Womens Hospital in Pittsburgh, United States.

Catheterization Methods for Postpartum Urinary Problems

18+
All Sexes
Pittsburgh, PA
At least ten percent of patients have postpartum urinary retention or difficulty urinating after birth, which can cause incontinence and other urinary problems long-term. After getting an epidural placed, patients should be numb in their pelvic region. This numbness makes it difficult to feel the need to urinate, so patients need a urinary catheter placed to empty the bladder. Some patients have one catheter placed throughout their labor and others have a catheter placed to empty the bladder then removed every few hours. The investigators are studying whether placing a catheter once or catheterizing multiple times affects the rate of postpartum urinary problems and infection.
Waitlist Available
Has No Placebo
UPMC Magee-Womens HospitalAnna Binstock, MD
Image of University of California, San Francisco in San Francisco, United States.

Trimethoprim-Sulfamethoxazole for Urinary Tract Infections

13 - 29
All Sexes
San Francisco, CA
The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months. The main questions this study is asking are: * Does TMP-SMX lower the number of UTIs in the first year after transplant? * What side effects or problems do participants have while taking TMP-SMX? Researchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs. Participants will: * Take either TMP-SMX or a placebo pill by mouth every day for 6 months * Have three visits to touch base with the study team about any issues * Complete short monthly online surveys about any symptoms or side effects * Share blood and urine test results from their regular transplant clinic visits
Phase 4
Waitlist Available
University of California, San FranciscoAlexandra Bicki, MD
Have you considered Augmentin Es-600 clinical trials? We made a collection of clinical trials featuring Augmentin Es-600, we think they might fit your search criteria.Go to Trials
Image of Children's Healthcare of Atlanta in Atlanta, United States.

Antibiotic Strategies for Pneumonia in Children

12 - 71
All Sexes
Atlanta, GA
The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with community-acquired pneumonia get better from their illness. The main aims of this study are: * To compare the effectiveness of SNAP versus immediate antibiotic prescribing in children with mild community-acquired pneumonia (CAP) * To identify which patient groups benefit most from the SNAP strategy * To identify factors that shape implementation of each prescribing strategy. Researchers will compare the SNAP strategy (where parents or guardians are instructed to give antibiotics only if their child is not improving after 72 hours, or sooner if they are worsening) to the immediate antibiotic prescribing strategy (where parents or guardians are instructed to give the antibiotics right after their healthcare visit) to see if one strategy is more effective than the other. Participants will be randomly assigned to either the immediate antibiotic group or the SNAP group at enrollment. Participation lasts 14 days with follow-up surveys at 4, 7, and 14 days after enrollment.
Recruiting
Has No Placebo
Children's Healthcare of Atlanta (+3 Sites)Todd Florin, MD, MSCE
Have you considered Augmentin Es-600 clinical trials? We made a collection of clinical trials featuring Augmentin Es-600, we think they might fit your search criteria.Go to Trials
Image of Benioff Children's Hospital - Oakland in Oakland, United States.

Decision Support for Lower Respiratory Infections in Children

6 - 17
All Sexes
Oakland, CA
Eliminating inappropriate antibiotic use in pediatric lower respiratory tract infections (LRTI) is the central focus of this research. LRTIs (pneumonia, bronchiolitis, and infection-related exacerbations of asthma) account for nearly one-third of all emergency department (ED) visits and 40% of all infection-related hospitalizations in US children. LRTIs also account for more antibiotic use in children's hospitals than any other condition, despite most LRTIs being viral in nature. Inappropriate antibiotics are associated with substantial adverse effects. Accordingly, national guidelines strongly discourage routine antibiotic use for bronchiolitis and acute asthma and argue for significantly reducing antibiotic exposure (initiation, spectrum, and duration) in pneumonia. To address the problem of inappropriate antibiotic use, hospital-based antimicrobial stewardship programs (ASPs) are now common nationwide, and these programs have demonstrated effectiveness in some hospital settings. Unfortunately, traditional ASP approaches do not translate well to the fast-paced and unpredictable ED environment, and hospital-based ASP resources are finite and not always immediately available. Clinical decision support (CDS) embedded within the electronic health record (EHR) is a strategy that could address the ED antibiotic stewardship gap. Informed by a deep understanding of the key facilitators and barriers to using CDS to support appropriate antibiotic use in ED and hospital settings, the investigators have developed two stewardship-focused CDS interventions for pediatric LRTI. The overarching goal of this research is to rigorously evaluate the implementation and effectiveness of these CDS tools, alone and in combination, against usual care only in a pragmatic randomized clinical trial at 3 U.S. children's hospitals.
Recruiting
Has No Placebo
Benioff Children's Hospital - Oakland (+2 Sites)Derek J Williams, MD, MPH
Image of Harbor UCLA Medical Center - Medicine - Infectious Diseases in Torrance, United States.

Optimized Beta-lactam Dosing for Bacterial Infections

18+
All Sexes
Torrance, CA
The purpose of this study is to evaluate the abilities of Cystatin C (CysC) and CysC-based estimated Glomerular Filtration Rate (eGFR) equations to characterize the pharmacokinetics (PK) profiles of meropenem and cefepime relative to Serum Creatinine (SCR), Serum Creatinine based Equation (SCRE)and iohexol at the population and individual levels in critically ill adult patients with suspected or documented AMR Gram-negative infections. We hypothesize that CysC and CysC-based eGFR equations will characterize the PK profiles of meropenem and cefepime at the population and individual levels with greater accuracy and precision than SCR and SCREs. Iohexol will be administered to patients enrolled in the study and serve as the reference indicator of measured Glomerular Filtration Rate (mGFR), which is the gold standard assessment of kidney function. We hypothesize that the predictive performances of CysC and CysC-based eGFR equations in estimating the PK profiles of meropenem and cefepime at the population and individual levels will be comparable to iohexol. The information obtained in this study will be used to develop PK/pharmacodynamics (PD) optimized meropenem and cefepime dosing schemes based on the renal function biomarker population PK (PopPK) model with the best predictive performance for clinical use in the treatment of critically ill adult patients with suspected or documented AMR Gram-negative infections and varying degrees of renal function. The primary objective of this study is to compare the abilities of renal function biomarkers (CysC, CysC-based eGFR equations, SCR, SCREs) relative to iohexol to characterize the PK profiles of meropenem and cefepime in critically ill adult patients with suspected or documented AMR Gram-negative infections.
Phase 4
Recruiting
Harbor UCLA Medical Center - Medicine - Infectious Diseases (+9 Sites)
Have you considered Augmentin Es-600 clinical trials? We made a collection of clinical trials featuring Augmentin Es-600, we think they might fit your search criteria.Go to Trials